Cadila set to introduce cut-price lung cancer drug in India
This article was originally published in Scrip
Executive Summary
Privately owned Indian firm, Cadila Pharmaceuticals, is set to launch Mycidac-C (heat-killed mycobacterium w), a desmocollin-3 targeting active immune therapy, for non-small cell lung cancer (NSCLC) on the domestic market.